Schrodinger Inc
SDGR
查看详细走势图
13.490USD
+0.550+4.25%
收盘 02/06, 16:00（美东）报价延迟15分钟
993.33M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.25%
5天
-3.44%
1月
-28.13%
6月
-30.32%
今年开始到现在
-24.55%
1年
-47.45%
查看详细走势图
TradingKey Schrodinger Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Schrodinger Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在软件与IT服务行业排名98/482位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价25.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Schrodinger Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Schrodinger Inc亮点
亮点风险
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
利润高增长
公司净利润处于行业前列，最新年度总收入207.54M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值合理
公司最新PE估值-5.62，处于3年历史合理位
机构减仓
最新机构持股70.83M股，环比减少9.79%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值515.00
分析师目标
根据
10
位分析师
买入
评级
25.000
目标均价
+87.13%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Schrodinger Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Schrodinger Inc简介
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
公司代码SDGR
公司Schrodinger Inc
CEOFarid (Ramy Farid)
网址https://www.schrodinger.com
相关品种
